Globus Medical (NYSE:GMED) Announces FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 4.950-5.050 for the period, compared to the consensus estimate of 5.000. The company issued revenue guidance of $3.1 billion, compared to the consensus revenue estimate of $3.2 billion.

Globus Medical Stock Performance

GMED opened at $81.13 on Friday. The stock has a fifty day moving average of $77.44 and a 200-day moving average of $83.29. The company has a market capitalization of $10.89 billion, a P/E ratio of 20.75, a P/E/G ratio of 1.40 and a beta of 0.98. Globus Medical has a fifty-two week low of $60.36 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm had revenue of $763.72 million for the quarter, compared to analyst estimates of $792.39 million. During the same quarter in the prior year, the business posted $1.18 EPS. The business’s revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities research analysts predict that Globus Medical will post 4.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GMED has been the topic of several analyst reports. UBS Group began coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price target on the stock. Royal Bank Of Canada dropped their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, October 1st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Wells Fargo & Company lowered their target price on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Finally, Truist Financial dropped their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $99.46.

Insider Activity

In related news, Director Ann Rhoads sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares in the company, valued at $3,007,640. This trade represents a 12.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James R. Tobin sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the sale, the director directly owned 15,000 shares in the company, valued at approximately $1,118,700. This represents a 66.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 60,000 shares of company stock valued at $4,838,400 over the last quarter. 18.38% of the stock is owned by company insiders.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical reported third-quarter EPS of $1.23, topping the $1.20 consensus and rising from $1.18 a year earlier. The company also increased its share-repurchase authorization by $500 million, which could support shareholder returns. Third-quarter results and repurchase program
• Positive Sentiment: The company’s acquisition of Synaptive Medical adds cranial-neurosurgery technology and may strengthen its position in cranial procedures. Globus Medical acquires neurosurgery technology
• Neutral Sentiment: Director Ann Rhoads sold 5,000 shares for $425,000, reducing her reported holdings by 12.38%. A single insider sale does not necessarily indicate a change in the company’s outlook. SEC ownership filing
• Negative Sentiment: Quarterly revenue was $763.7 million, below analysts’ $792.4 million estimate and down 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion also trails the $3.2 billion consensus; EPS guidance of $4.95–$5.05 is broadly in line with the $5.00 estimate. The sales miss and softer revenue outlook likely outweighed the EPS beat. Quarterly results and guidance

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.